Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age

Vaccine

Volumn 29, Issue 6, 2011, Pages 1324-1331

  Diaz Mitoma, Francisco ^a   Halperin, Scott A ^b   Tapiero, Bruce ^c   Hoffenbach, Agnes ^d   Zappacosta, Pamela S ^e   Radley, David ^e   Bradshaw, Susan ^e   Martin, Jason C ^e   Boslego, John W ^e   Hesley, Teresa M ^e   Bhuyan, Prakash K ^e   Silber, Jeffrey L ^e  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b IWK HEALTH CENTRE   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d SANOFI PASTEUR   (France)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Combination vaccine; Diphtheria tetanus acellular pertussis inactivated poliovirus Haemophilus influenzae b conjugate hepatitis B vaccine; Liquid vaccine; Vaccine safety and immunogenicity

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; NEISSERIA MENINGITIDIS OUTER MEMBRANE PROTEIN COMPLEX; OUTER MEMBRANE PROTEIN; PENTACEL; POLYRIBOSYLRIBITOL PHOSPHATE; POLYSACCHARIDE; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHMA; ATELECTASIS; BACTEREMIA; BRONCHIOLITIS; CHILD; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EYE DISCHARGE; FEMALE; GROUPS BY AGE; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; LIQUID; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SIDE EFFECT; URINARY TRACT INFECTION; VACCINATION REACTION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; MALE; POLIOVIRUS VACCINE, INACTIVATED; SKIN DISEASES; VACCINES, CONJUGATE;

EID: 78751574075     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.053     Document Type: Article

References (29)

1. Parrino J., Graham B.S. Smallpox vaccines: past, present, and future. J Allergy Clin Immunol 2006, 118(December (6)):1320-1326.
2. Halperin S.A., Tapiero B., Diaz-Mitoma F., Law B.J., Hoffenbach A., Zappacosta P.S., et al. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. Vaccine 2009, 27(April (19)):2540-2547.
3. Bellanti J.A. Immunization update and hot topics in clinical immunology: how does this relate to my practice? Allergy Asthma Proc 2006, 27(November-December (6)):456-464.
4. Dutta A. Epidemiology of poliomyelitis-options and update. Vaccine 2008, 26(October (45)):5767-5773.
5. Boog C.J. Principles of vaccination and possible development strategies for rational design. Immunol Lett 2009, 122(February (2)):104-107.
6. Duclos P., Okwo-Bele J.M., Gacic-Dobo M., Cherian T. Global immunization: status, progress, challenges and future. BMC Int Health Hum Rights 2009, 9(Suppl. 1):S2.
7. Progress in global measles control and mortality reduction, 2000-2006. Wkly Epidemiol Rec 2007, 82(November (48)):418-424.
8. Moss W.J. Measles control and the prospect of eradication. Curr Top Microbiol Immunol 2009, 330:173-189.
9. Morris S.K., Moss W.J., Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 2008, 8(July (7)):435-443.
10. Zhou F., Bisgard K.M., Yusuf H.R., Deuson R.R., Bath S.K., Murphy T.V. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics 2002, 110(October (4)):653-661.
11. Chien Y.C., Jan C.F., Kuo H.S., Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006, 28:126-135.
12. Chang M.H. Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res 2009, 181:85-94.
13. Ten great public health achievements-United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999, 48(April (12)):241-243.
14. Khan M.M. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV? Vaccine 2008, 26(April (16)):2034-2040.
15. Happe L.E., Lunacsek O.E., Kruzikas D.T., Marshall G.S. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. Pediatr Infect Dis J 2009, 28(February (2)):98-101.
16. Koslap-Petraco M.B., Judelsohn R.G. Societal impact of combination vaccines: experiences of physicians, nurses, and parents. J Pediatr Health Care 2008, 22(September-October (5)):300-309.
17. Marshall G.S., Happe L.E., Lunacsek O.E., Szymanski M.D., Woods C.R., Zahn M., et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007, 26(June (6)):496-500.
18. Koslap-Petraco M.B., Parsons T. Communicating the benefits of combination vaccines to parents and health care providers. J Pediatr Health Care 2003, 17(March-April (2)):53-57.
19. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep 2008, 57(October (39)):1079-1080.
20. Dhillon S., Keam S.J. DTaP-IPV/Hib vaccine (Pentacel). Paediatr Drugs 2008, 10(6):405-416.
21. Venters C., Graham W., Cassidy W. Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines 2004, 3(April (2)):119-129.
22. Immunization NACo. Canadian immunization guide 2006, Public Health Agency of Canada, Ottawa. 7th ed.
23. Recommended Immunization Schedules for Persons Aged 0 Through 18 Years-United States. MMWR Morb Mortal Wkly Rep 2009, 57(51 & 52):Q1-Q4.
24. Decker M.D., Edwards K.M. Haemophilus influenzae type b vaccines: history, choice and comparisons. Pediatr Infect Dis J 1998, 17(September (9 Suppl.)):S113-S116.
25. Mehrotra D.V., Heyse J.F. Use of the false discovery rate for evaluating clinical safety data. Stat Methods Med Res 2004, 13(June (3)):227-238.
26. Hochberg Y., Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990, 9(July (7)):811-818.
27. Halperin S.A., Langley J.M., Hesley T.M., Zappacosta P.S., Radley D., Smith B., et al. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children. Hum Vaccin 2005, 1(November-December (6)):245-250.
28. Nolan T., Hogg G., Darcy M.A., Skeljo M., Carlin J., Boslego J. A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity. Vaccine 2001, 19(February (15-16)):2127-2137.
29. Ambrosino D.M., Bolon D., Collard H., Van Etten R., Kanchana M.V., Finberg R.W. Effect of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate vaccine on macrophages. J Immunol 1992, 149(December (12)):3978-3983.